Regulatory Q&A Forum
Ask questions, share knowledge, and get help from the regulatory community
For manufacturers of Class II in vitro diagnostic (IVD) devices, how do the foundational regulations, device-specific special controls, and associated FDA guidance documents interact to form the compl...
As global Extended Producer Responsibility (EPR) and Waste from Electrical and Electronic Equipment (WEEE) regulations become more complex, particularly with ongoing discussions around potential revis...
Given the significant revisions to the EU WEEE Directive anticipated around 2026, how can a medical device manufacturer move beyond basic compliance and strategically select a Producer Responsibility ...
How can a medical device manufacturer effectively evaluate a biocompatibility testing laboratory's readiness for significant upcoming updates to international standards like ISO 10993? Selecting a par...
Given the anticipated updates to the ISO 10993 series of standards, how should medical device manufacturers strategically evaluate and select a contract research organization (CRO) for biocompatibilit...
With the UK medical device regulatory landscape continuing to evolve ahead of significant expected changes, non-UK manufacturers face the critical task of appointing a UK Responsible Person (UKRP). Be...
What key criteria and due diligence steps should a non-EU medical device manufacturer implement when selecting an EU Authorised Representative (AR) to ensure long-term compliance with the Medical Devi...
As the EU cosmetics landscape prepares for significant regulatory updates anticipated around 2026, including potential new ingredient restrictions and revised labeling rules, how should a non-EU brand...
With significant revisions to the EU WEEE Directive anticipated for 2026, including higher collection targets and potentially new reporting obligations, how should a medical device manufacturer, as a ...
With significant updates to EU environmental regulations, including revisions to the WEEE Directive and various national Extended Producer Responsibility (EPR) frameworks anticipated around 2026, how ...
With international standards like ISO 10993 undergoing periodic revisions, how can medical device manufacturers develop a robust strategy for selecting a contract research organization (CRO) for bioco...
As internationally recognized biocompatibility standards continue to evolve, what is a comprehensive and proactive framework for medical device manufacturers to adapt their biological evaluation strat...
As the transitional arrangements for medical device compliance in Great Britain approach their deadlines, how should a non-UK manufacturer develop a comprehensive strategy for selecting a UK Responsib...
With significant updates to the UK's medical device regulations on the horizon, non-UK manufacturers face a critical deadline to ensure compliance. A key requirement is the appointment of a UK Respons...
For a non-US medical device manufacturer preparing to enter the US market, the requirement to designate a US Agent can seem like a simple administrative step. However, the choice of a US Agent has sig...
With significant updates to the EU's regulatory landscape for cosmetics expected through 2026, how can a non-EU brand move beyond a basic checklist to select a truly effective Responsible Person (RP) ...
For manufacturers of connected medical devices, such as an integrated continuous glucose monitoring system (iCGM) governed by regulations like 21 CFR 862.1355, preparing for global market entry requir...
For a medical device premarket submission, what are the key components of a robust cybersecurity documentation package that effectively demonstrates a proactive security posture to regulators like the...
With international standards for biocompatibility, such as the ISO 10993 series, undergoing periodic revisions, how can medical device manufacturers proactively adapt their regulatory strategies for s...
With international biocompatibility standards continually evolving, how can medical device manufacturers move beyond a simple checklist approach and develop a robust, risk-based biological evaluation ...